ANZ DATA

AUSTRALIA &
NEW ZEALAND
DIALYSIS & TRANSPLANT
REGISTRY

MISSING DATA REPORT

Survey Data 2017 – 2021

Abstract

The rates of non-response for ANZDATA
survey items over the last 5 years

anzdata@anzdata.org.au
www.anzdata.org.au

ANZDATA Missing Data Report

The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2017	2018	2019	2020	2021
Frequency	3777	3845	3948	4023	3991
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	49 (1.3%)	68 (1.8%)	30 (0.8%)	10 (0.2%)	50 (1.3%)
Late referral seen <3 mths before 1st treatment	75 (2.0%)	93 (2.4%)	56 (1.4%)	32 (0.8%)	72 (1.8%)
Ethnicity 1	156 (4.1%)	143 (3.7%)	82 (2.1%)	82 (2.0%)	81 (2.0%)
Primary kidney disease	83 (2.2%)	106 (2.8%)	60 (1.5%)	62 (1.5%)	62 (1.6%)
Was native kidney biopsied?	107 (2.8%)	102 (2.7%)	115 (2.9%)	38 (0.9%)	74 (1.9%)
Serum creatinine at entry	92 (2.4%)	104 (2.7%)	71 (1.8%)	53 (1.3%)	61 (1.5%)
Height at KRT entry (cm)	122 (3.2%)	113 (2.9%)	178 (4.5%)	74 (1.8%)	79 (2.0%)
Weight at KRT entry (kg)	67 (1.8%)	64 (1.7%)	97 (2.5%)	21 (0.5%)	71 (1.8%)
Smoking status at KRT entry	109 (2.9%)	101 (2.6%)	115 (2.9%)	47 (1.2%)	93 (2.3%)

Table 2 Comorbidities at KRT entry

Variable	2017	2018	2019	2020	2021
Frequency	3777	3845	3948	4023	3991
Postcode	56 (1.5%)	68 (1.8%)	55 (1.4%)	19 (0.5%)	55 (1.4%)
Chronic lung disease	23 (0.6%)	23 (0.6%)	67 (1.7%)	26 (0.6%)	6 (0.2%)
Coronary artery disease	23 (0.6%)	23 (0.6%)	68 (1.7%)	27 (0.7%)	5 (0.1%)
Peripheral vascular disease	23 (0.6%)	23 (0.6%)	66 (1.7%)	25 (0.6%)	4 (0.1%)
Cerebrovascular disease	23 (0.6%)	23 (0.6%)	67 (1.7%)	26 (0.6%)	6 (0.2%)
Diabetes	19 (0.5%)	27 (0.7%)	38 (1.0%)	21 (0.5%)	58 (1.5%)
Cancer ever diagnosed?	47 (1.2%)	22 (0.6%)	88 (2.2%)	10 (0.2%)	125 (3.1%)
Hepatitis C Antibody	61 (1.6%)	124 (3.2%)	125 (3.2%)	36 (0.9%)	148 (3.7%)
Calciphylaxis Episode	3748 (99.2%)	3775 (98.2%)	594 (15.0%)	11 (0.3%)	55 (1.4%)
Non-Registry Trials	3753 (99.4%)	3787 (98.5%)	744 (18.8%)	117 (2.9%)	791 (19.8%)

ANZDATA Missing Data Report

Table 3 Comorbidities at survey date

Variable	2017	2018	2019	2020	2021
Frequency	33259	34405	35736	36997	38239
Postcode	413 (1.2%)	418 (1.2%)	397 (1.1%)	113 (0.3%)	423 (1.1%)
Chronic lung disease	134 (0.4%)	105 (0.3%)	147 (0.4%)	146 (0.4%)	133 (0.3%)
Coronary artery disease	132 (0.4%)	105 (0.3%)	148 (0.4%)	146 (0.4%)	132 (0.3%)
Peripheral vascular disease	132 (0.4%)	105 (0.3%)	146 (0.4%)	145 (0.4%)	131 (0.3%)
Cerebrovascular disease	135 (0.4%)	108 (0.3%)	150 (0.4%)	149 (0.4%)	135 (0.4%)
Diabetes	125 (0.4%)	108 (0.3%)	124 (0.3%)	125 (0.3%)	167 (0.4%)
Cancer ever diagnosed?	177 (0.5%)	78 (0.2%)	121 (0.3%)	96 (0.3%)	210 (0.5%)
Hepatitis C Antibody	199 (0.6%)	233 (0.7%)	227 (0.6%)	189 (0.5%)	296 (0.8%)
Calciphylaxis Episode	33208 (99.8%)	34240 (99.5%)	1551 (4.3%)	848 (2.3%)	841 (2.2%)
Non-Registry Trials	33222 (99.9%)	34267 (99.6%)	3709 (10.4%)	1128 (3.0%)	3016 (7.9%)

Table 4 Reason for change from CAPD to APD

Variable	2017	2018	2019	2020	2021
Frequency	623	643	653	628	615
Reason transfer from dialysis during survey	33 (5.3%)	24 (3.7%)	72 (11.0%)	52 (8.3%)	121 (19.7%)

Table 5 Reason for change from APD to CAPD

Variable	2017	2018	2019	2020	2021
Frequency	142	83	110	104	165
Reason transfer from dialysis during survey	18 (12.7%)	4 (4.8%)	15 (13.6%)	15 (14.4%)	68 (41.2%)

Table 6 Reason for change from PD to HD

Variable	2017	2018	2019	2020	2021
Frequency	810	810	799	835	909
Reason transfer from dialysis during survey	51 (6.3%)	35 (4.3%)	68 (8.5%)	49 (5.9%)	79 (8.7%)

Table 7 Reason for change from HD to PD

Variable	2017	2018	2019	2020	2021
Frequency	553	525	528	518	495
Reason transfer from dialysis during survey	31 (5.6%)	18 (3.4%)	23 (4.4%)	30 (5.8%)	54 (10.9%)

Table 8 Cause of death

Variable	2017	2018	2019	2020	2021
Frequency	2699	2624	2766	2750	2782
Cause of death	107 (4.0%)	67 (2.6%)	67 (2.4%)	55 (2.0%)	36 (1.3%)

ANZDATA Missing Data Report

Table 9 Dialysis data

Variable	2017	2018	2019	2020	2021
Frequency	19548	19963	20514	21058	21781
Dialysis type	211 (1.1%)	851 (4.3%)	935 (4.6%)	987 (4.7%)	1125 (5.2%)
Self-care dialysis (performed by the patient with minimal assistance)	19548 (100.0%)	19963 (100.0%)	20514 (100.0%)	1192 (5.7%)	1191 (5.5%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	1003 (5.1%)	899 (4.5%)	981 (4.8%)	1114 (5.3%)	1469 (6.7%)
Uncorrected calcium levels (mmol/l)	935 (4.8%)	879 (4.4%)	1109 (5.4%)	1391 (6.6%)	1329 (6.1%)
Phosphate levels (mmol/l)	916 (4.7%)	851 (4.3%)	1111 (5.4%)	1365 (6.5%)	1344 (6.2%)
Haemoglobin level nearest end Survey (g/l)	931 (4.8%)	852 (4.3%)	1100 (5.4%)	1351 (6.4%)	1313 (6.0%)
EPO Agent	943 (4.8%)	848 (4.2%)	1031 (5.0%)	1197 (5.7%)	1668 (7.7%)
Ferritin within last 3 months of Survey	2044 (10.5%)	1948 (9.8%)	2015 (9.8%)	2539 (12.1%)	2449 (11.2%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	2431 (12.4%)	2534 (12.7%)	2710 (13.2%)	2896 (13.8%)	2685 (12.3%)

Table 10 Haemodialysis data

Variable	2017	2018	2019	2020	2021
Frequency	15870	16293	16887	17370	18025
Dialyser brand, model, membrane, surface area	833 (5.2%)	750 (4.6%)	995 (5.9%)	852 (4.9%)	931 (5.2%)
Blood flow rate (mls/min)	832 (5.2%)	757 (4.6%)	994 (5.9%)	863 (5.0%)	943 (5.2%)
Frequency of dialysis per week	806 (5.1%)	722 (4.4%)	967 (5.7%)	835 (4.8%)	922 (5.1%)
Hours per session	830 (5.2%)	749 (4.6%)	984 (5.8%)	850 (4.9%)	960 (5.3%)
Adequacy method (urea reduction or Kt/V)	3010 (19.0%)	3038 (18.6%)	3610 (21.4%)	3137 (18.1%)	3442 (19.1%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	3031 (19.1%)	3038 (18.6%)	3610 (21.4%)	3137 (18.1%)	3459 (19.2%)
Vascular access in use at last haemodialysis	852 (5.4%)	769 (4.7%)	1036 (6.1%)	886 (5.1%)	1018 (5.6%)

Table 11 HDF volume

Variable	2017	2018	2019	2020	2021
Frequency	4531	5302	5101	5243	4983
HDF volume (L) (If on HDF)	4531 (100.0%)	5299 (99.9%)	789 (15.5%)	653 (12.5%)	478 (9.6%)

Table 12 Access at first HD

Variable	2017	2018	2019	2020	2021
Frequency	3120	3183	3330	3290	3373
Vascular access in use at first haemodialysis	114 (3.7%)	98 (3.1%)	149 (4.5%)	116 (3.5%)	90 (2.7%)

ANZDATA Missing Data Report

Table 13 Peritoneal dialysis data

Variable	2017	2018	2019	2020	2021
Frequency	4795	4779	4729	4845	4908
Type of Peritoneal Connection System	258 (5.4%)	195 (4.1%)	255 (5.4%)	287 (5.9%)	371 (7.6%)
Total volume weekly exchanges - All PD	252 (5.3%)	175 (3.7%)	327 (6.9%)	314 (6.5%)	651 (13.3%)
PD Solution Glucose	250 (5.2%)	163 (3.4%)	268 (5.7%)	302 (6.2%)	428 (8.7%)
PD Solution Iodextrin	251 (5.2%)	163 (3.4%)	282 (6.0%)	303 (6.3%)	429 (8.7%)
PD Solution Low GDP (either Lactate or Bicarbonate)	247 (5.2%)	165 (3.5%)	270 (5.7%)	308 (6.4%)	432 (8.8%)
Creatinine Clearance (litres per week)	1582 (33.0%)	1472 (30.8%)	1647 (34.8%)	1961 (40.5%)	2125 (43.3%)
Dialysate Only Weekly Kt/V value on PD	1572 (32.8%)	1481 (31.0%)	1639 (34.7%)	1958 (40.4%)	2106 (42.9%)
Residual kidney function (creatinine clearance - GFR)	1616 (33.7%)	1491 (31.2%)	1662 (35.1%)	1968 (40.6%)	2140 (43.6%)
Number of episodes peritonitis during survey	676 (14.1%)	874 (18.3%)	771 (16.3%)	926 (19.1%)	1175 (23.9%)
Residual Urine Volume (mL/24 hrs)	4795 (100.0%)	4778 (100.0%)	2704 (57.2%)	2843 (58.7%)	2603 (53.0%)

Table 14 Peritoneal dialysis PET test

Variable	2017	2018	2019	2020	2021
Frequency	1409	1393	1364	1526	1450
PET test for PD-within first 6 mths starting?	1320 (93.7%)	1258 (90.3%)	974 (71.4%)	994 (65.1%)	964 (66.5%)

Table 15 Peritonitis episodes data

Variable	2017	2018	2019	2020	2021
Frequency	1089	1146	989	996	1084
Was this a relapse or recurrence of peritonitis?	140 (12.9%)	106 (9.2%)	119 (12.0%)	19 (1.9%)	24 (2.2%)
Technique at time of infection	3 (0.3%)	8 (0.7%)	4 (0.4%)	3 (0.3%)	1 (0.1%)
Antifungal Therapy?	168 (15.4%)	108 (9.4%)	179 (18.1%)	52 (5.2%)	32 (3.0%)
Name of initial regimen first antibiotic given	141 (12.9%)	100 (8.7%)	117 (11.8%)	26 (2.6%)	7 (0.6%)
Name of final regimen first antibiotic given	156 (14.3%)	126 (11.0%)	156 (15.8%)	54 (5.4%)	73 (6.7%)
Glucose PD Solution at time of infection?	188 (17.3%)	144 (12.6%)	148 (15.0%)	57 (5.7%)	50 (4.6%)
Icodextrin PD Solution at time of infection?	190 (17.4%)	144 (12.6%)	150 (15.2%)	62 (6.2%)	50 (4.6%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	207 (19.0%)	164 (14.3%)	152 (15.4%)	66 (6.6%)	51 (4.7%)
Was patient hospitalised overnight?	138 (12.7%)	103 (9.0%)	129 (13.0%)	45 (4.5%)	5 (0.5%)
Was catheter removed?	134 (12.3%)	104 (9.1%)	117 (11.8%)	40 (4.0%)	11 (1.0%)
Did patient have interim haemodialysis?	154 (14.1%)	131 (11.4%)	136 (13.8%)	42 (4.2%)	11 (1.0%)
Did patient transfer to permanent haemodialysis?	155 (14.2%)	128 (11.2%)	120 (12.1%)	44 (4.4%)	16 (1.5%)

ANZDATA Missing Data Report

Table 16 Transplant baseline data

Variable	2017	2018	2019	2020	2021
Frequency	1290	1317	1315	1072	1044
Recipient CMV antibody status	51 (4.0%)	4 (0.3%)	25 (1.9%)	54 (5.0%)	28 (2.7%)
Recipient EBV antibody status	49 (3.8%)	4 (0.3%)	27 (2.1%)	55 (5.1%)	29 (2.8%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	59 (4.6%)	16 (1.2%)	82 (6.2%)	35 (3.3%)	22 (2.1%)
Immediate function	29 (2.2%)	12 (0.9%)	26 (2.0%)	18 (1.7%)	13 (1.2%)
HLA-A mismatch	23 (1.8%)	2 (0.2%)	5 (0.4%)	9 (0.8%)	0 (0.0%)
HLA-B mismatch	23 (1.8%)	2 (0.2%)	5 (0.4%)	9 (0.8%)	0 (0.0%)
HLA-DR mismatch	23 (1.8%)	2 (0.2%)	5 (0.4%)	9 (0.8%)	0 (0.0%)
HLA-DQ mismatch	536 (41.6%)	485 (36.8%)	189 (14.4%)	86 (8.0%)	18 (1.7%)
Donor blood group	1 (0.1%)	0 (0.0%)	0 (0.0%)	4 (0.4%)	0 (0.0%)
Recipient blood group	0 (0.0%)	1 (0.1%)	0 (0.0%)	3 (0.3%)	0 (0.0%)
Recipient authorised match PRA from OrganMatch	120 (9.3%)	239 (18.1%)	6 (0.5%)	9 (0.8%)	0 (0.0%)

Table 17 Transplant Surgical data - of all transplants

Variable	2017	2018	2019	2020	2021
Frequency	1290	1317	1315	1072	1044
At least one anastomosis in transplant surgical data	1290 (100.0%)	1317 (100.0%)	803 (61.1%)	245 (22.9%)	98 (9.4%)

Table 18 Transplant Surgical data - of all anatomoses

Variable	2017	2018	2019	2020	2021
Frequency	0	0	545	896	977
Anastomosis site	-	-	0 (0.0%)	0 (0.0%)	0 (0.0%)
Arterial	-	-	27 (5.0%)	32 (3.6%)	28 (2.9%)
Venous	-	-	27 (5.0%)	35 (3.9%)	28 (2.9%)
Vena cava extension	-	-	32 (5.9%)	33 (3.7%)	8 (0.8%)
Aortic patch	-	-	31 (5.7%)	30 (3.3%)	6 (0.6%)
Anastomosis time (min)	-	-	64 (11.7%)	56 (6.3%)	30 (3.1%)

Table 19 Graft failure data

Variable	2017	2018	2019	2020	2021
Frequency	321	370	316	315	331
Cause of graft failure	36 (11.2%)	25 (6.8%)	52 (16.5%)	18 (5.7%)	11 (3.3%)
Serum creatinine at graft failure	123 (38.3%)	39 (10.5%)	67 (21.2%)	34 (10.8%)	19 (5.7%)

ANZDATA Missing Data Report

Table 20 Rejection data

Variable	2017	2018	2019	2020	2021
Frequency	541	473	408	408	354
Was a biopsy performed?	2 (0.4%)	2 (0.4%)	2 (0.5%)	0 (0.0%)	0 (0.0%)
Response of this rejection to treatment	40 (7.4%)	57 (12.1%)	26 (6.4%)	44 (10.8%)	41 (11.6%)
Primary treatment of rejection	10 (1.8%)	19 (4.0%)	2 (0.5%)	20 (4.9%)	10 (2.8%)

Table 21 Rejection data if biopsy performed

Variable	2017	2018	2019	2020	2021
Frequency	529	462	401	403	341
If biopsy is Yes ?Cellular	17 (3.2%)	23 (5.0%)	4 (1.0%)	328 (81.4%)	341 (100.0%)
If biopsy is Yes ?Glomerular	17 (3.2%)	19 (4.1%)	14 (3.5%)	327 (81.1%)	341 (100.0%)
If biopsy is Yes ?Vascular	24 (4.5%)	23 (5.0%)	13 (3.2%)	327 (81.1%)	341 (100.0%)
Humoral Rejection	17 (3.2%)	27 (5.8%)	29 (7.2%)	327 (81.1%)	341 (100.0%)
If biopsy is Yes ?Antibody mediated	529 (100.0%)	462 (100.0%)	401 (100.0%)	163 (40.4%)	6 (1.8%)
If biopsy is Yes ?T-cell mediated	529 (100.0%)	462 (100.0%)	401 (100.0%)	155 (38.5%)	6 (1.8%)
If biopsy is Yes ?Presence of donor specific antibody(DSA)	529 (100.0%)	462 (100.0%)	401 (100.0%)	333 (82.6%)	227 (66.6%)
If biopsy is Yes and Banff g is known	39 (7.4%)	35 (7.6%)	22 (5.5%)	41 (10.2%)	32 (9.4%)
If biopsy is Yes and Banff i is known	38 (7.2%)	35 (7.6%)	19 (4.7%)	38 (9.4%)	35 (10.3%)
If biopsy is Yes and Banff t is known	38 (7.2%)	33 (7.1%)	20 (5.0%)	34 (8.4%)	31 (9.1%)
If biopsy is Yes and Banff v is known	47 (8.9%)	39 (8.4%)	21 (5.2%)	45 (11.2%)	55 (16.1%)
If biopsy is Yes and Banff ptc is known	228 (43.1%)	135 (29.2%)	52 (13.0%)	48 (11.9%)	46 (13.5%)
If biopsy is Yes and Banff c4d is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	200 (49.6%)	81 (23.8%)
If biopsy is Yes and Banff cg is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	206 (51.1%)	70 (20.5%)
If biopsy is Yes and Banff ci is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	218 (54.1%)	66 (19.4%)
If biopsy is Yes and Banff ct is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	217 (53.8%)	66 (19.4%)
If biopsy is Yes and Banff cv is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	218 (54.1%)	77 (22.6%)
If biopsy is Yes and Banff mm is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	237 (58.8%)	129 (37.8%)
If biopsy is Yes and Banff ah is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	203 (50.4%)	77 (22.6%)
If biopsy is Yes and Banff ti is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	235 (58.3%)	113 (33.1%)
If biopsy is Yes and Banff i-IFTA is known	529 (100.0%)	462 (100.0%)	401 (100.0%)	251 (62.3%)	137 (40.2%)

Table 22 Rejection data if biopsy not performed

Variable	2017	2018	2019	2020	2021
Frequency	10	9	5	5	13
Likelihood of rejection if biopsy not performed	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 23 Rejection data - AMR

Variable	2017	2018	2019	2020	2021
Frequency	0	0	0	0	73
History of Non-Adherence?	-	-	-	-	54 (74.0%)
CNI Type	-	-	-	-	54 (74.0%)
CNI Level type code	-	-	-	-	54 (74.0%)
CNI Level	-	-	-	-	57 (78.1%)
MMF dose (mg)(daily)	-	-	-	-	57 (78.1%)
MPA dose (mg)(daily)	-	-	-	-	68 (93.2%)
Prednisolone dose (mg)(daily)	-	-	-	-	54 (74.0%)
Creatinine umol/L	-	-	-	-	54 (74.0%)
Urine Protein / Creatinine Ratio	-	-	-	-	65 (89.0%)
Albumin / Creatinine Ratio	-	-	-	-	68 (93.2%)
New-onset CMV Viraemia in the preceding 12 months?	-	-	-	-	56 (76.7%)
New-onset BK Viraemia in the preceding 12 months?	-	-	-	-	56 (76.7%)
Parenthood in last 12 months?	-	-	-	-	56 (76.7%)

Table 24 Transplant follow-up data, 0 months

Variable	2017	2018	2019	2020	2021
Frequency	1313	1349	1336	1074	1048
Weight	68 (5.2%)	63 (4.7%)	71 (5.3%)	54 (5.0%)	25 (2.4%)
Drug data	61 (4.6%)	68 (5.0%)	40 (3.0%)	20 (1.9%)	27 (2.6%)

Table 25 Transplant follow-up data, 1 months

Variable	2017	2018	2019	2020	2021
Frequency	1309	1331	1325	1051	1012
Weight	50 (3.8%)	52 (3.9%)	35 (2.6%)	44 (4.2%)	61 (6.0%)
Serum creatinine	46 (3.5%)	42 (3.2%)	28 (2.1%)	25 (2.4%)	57 (5.6%)
Drug data	34 (2.6%)	28 (2.1%)	27 (2.0%)	26 (2.5%)	67 (6.6%)

Table 26 Transplant follow-up data, 2 months

Variable	2017	2018	2019	2020	2021
Frequency	1315	1336	1322	1048	1042
Weight	88 (6.7%)	57 (4.3%)	59 (4.5%)	73 (7.0%)	108 (10.4%)
Serum creatinine	57 (4.3%)	38 (2.8%)	46 (3.5%)	45 (4.3%)	83 (8.0%)
Drug data	52 (4.0%)	25 (1.9%)	53 (4.0%)	50 (4.8%)	99 (9.5%)

ANZDATA Missing Data Report

Table 27 Transplant follow-up data, 3 months

Variable	2017	2018	2019	2020	2021
Frequency	1303	1310	1291	1085	1044
Weight	141 (10.8%)	83 (6.3%)	86 (6.7%)	85 (7.8%)	126 (12.1%)
Serum creatinine	86 (6.6%)	52 (4.0%)	67 (5.2%)	61 (5.6%)	103 (9.9%)
Drug data	80 (6.1%)	40 (3.1%)	70 (5.4%)	67 (6.2%)	110 (10.5%)

Table 28 Transplant follow-up data, 6 months

Variable	2017	2018	2019	2020	2021
Frequency	1275	1288	1300	1067	1104
Weight	195 (15.3%)	148 (11.5%)	156 (12.0%)	151 (14.2%)	195 (17.7%)
Serum creatinine	96 (7.5%)	101 (7.8%)	111 (8.5%)	108 (10.1%)	139 (12.6%)
Drug data	106 (8.3%)	91 (7.1%)	120 (9.2%)	114 (10.7%)	154 (13.9%)

Table 29 Transplant follow-up data, 12 months

Variable	2017	2018	2019	2020	2021
Frequency	1221	1260	1292	1276	1026
Weight	147 (12.0%)	147 (11.7%)	166 (12.8%)	194 (15.2%)	171 (16.7%)
Serum creatinine	83 (6.8%)	104 (8.3%)	109 (8.4%)	147 (11.5%)	120 (11.7%)
Drug data	79 (6.5%)	99 (7.9%)	107 (8.3%)	135 (10.6%)	131 (12.8%)

Table 30 Transplant follow-up data, 24 months

Variable	2017	2018	2019	2020	2021
Frequency	1018	1184	1228	1268	1249
Weight	131 (12.9%)	157 (13.3%)	163 (13.3%)	218 (17.2%)	212 (17.0%)
Serum creatinine	75 (7.4%)	109 (9.2%)	101 (8.2%)	138 (10.9%)	151 (12.1%)
Drug data	72 (7.1%)	105 (8.9%)	105 (8.6%)	146 (11.5%)	166 (13.3%)

Table 31 Transplant follow-up data, 36 months

Variable	2017	2018	2019	2020	2021
Frequency	960	991	1151	1198	1239
Weight	150 (15.6%)	122 (12.3%)	165 (14.3%)	223 (18.6%)	228 (18.4%)
Serum creatinine	88 (9.2%)	80 (8.1%)	97 (8.4%)	156 (13.0%)	127 (10.3%)
Drug data	85 (8.9%)	83 (8.4%)	99 (8.6%)	158 (13.2%)	140 (11.3%)

Table 32 Transplant follow-up data, 60 months

Variable	2017	2018	2019	2020	2021
Frequency	808	851	890	916	1083
Weight	133 (16.5%)	132 (15.5%)	148 (16.6%)	181 (19.8%)	208 (19.2%)
Serum creatinine	65 (8.0%)	91 (10.7%)	95 (10.7%)	112 (12.2%)	132 (12.2%)
Drug data	61 (7.5%)	92 (10.8%)	101 (11.3%)	117 (12.8%)	141 (13.0%)

Table 33 Transplant follow-up data, 84 months

Variable	2017	2018	2019	2020	2021
Frequency	741	732	751	782	823
Weight	122 (16.5%)	106 (14.5%)	130 (17.3%)	158 (20.2%)	165 (20.0%)
Serum creatinine	76 (10.3%)	78 (10.7%)	66 (8.8%)	109 (13.9%)	104 (12.6%)
Drug data	74 (10.0%)	79 (10.8%)	79 (10.5%)	107 (13.7%)	112 (13.6%)

Table 34 Transplant follow-up data, 120 months

Variable	2017	2018	2019	2020	2021
Frequency	499	604	637	644	629
Weight	76 (15.2%)	105 (17.4%)	103 (16.2%)	134 (20.8%)	129 (20.5%)
Serum creatinine	47 (9.4%)	69 (11.4%)	62 (9.7%)	93 (14.4%)	83 (13.2%)
Drug data	50 (10.0%)	72 (11.9%)	76 (11.9%)	97 (15.1%)	89 (14.1%)

Table 35 Transplant follow-up data, 180 months

Variable	2017	2018	2019	2020	2021
Frequency	366	313	375	353	360
Weight	48 (13.1%)	57 (18.2%)	71 (18.9%)	70 (19.8%)	78 (21.7%)
Serum creatinine	28 (7.7%)	37 (11.8%)	44 (11.7%)	47 (13.3%)	46 (12.8%)
Drug data	31 (8.5%)	39 (12.5%)	49 (13.1%)	52 (14.7%)	52 (14.4%)

Table 36 Transplant follow-up data, 240 months

Variable	2017	2018	2019	2020	2021
Frequency	198	187	201	222	218
Weight	32 (16.2%)	34 (18.2%)	37 (18.4%)	53 (23.9%)	50 (22.9%)
Serum creatinine	22 (11.1%)	24 (12.8%)	24 (11.9%)	36 (16.2%)	37 (17.0%)
Drug data	24 (12.1%)	24 (12.8%)	27 (13.4%)	39 (17.6%)	39 (17.9%)

Table 37 Transplant follow-up data, 300 months

Variable	2017	2018	2019	2020	2021
Frequency	94	77	98	108	133
Weight	18 (19.1%)	16 (20.8%)	19 (19.4%)	28 (25.9%)	36 (27.1%)
Serum creatinine	11 (11.7%)	9 (11.7%)	10 (10.2%)	22 (20.4%)	19 (14.3%)
Drug data	15 (16.0%)	10 (13.0%)	12 (12.2%)	21 (19.4%)	20 (15.0%)

Table 38 Transplant follow-up data, 360 months

Variable	2017	2018	2019	2020	2021
Frequency	45	54	55	50	60
Weight	9 (20.0%)	10 (18.5%)	10 (18.2%)	10 (20.0%)	18 (30.0%)
Serum creatinine	8 (17.8%)	5 (9.3%)	6 (10.9%)	7 (14.0%)	11 (18.3%)
Drug data	4 (8.9%)	5 (9.3%)	8 (14.5%)	6 (12.0%)	11 (18.3%)

Table 39 Transplant follow-up data, 420 months

Variable	2017	2018	2019	2020	2021
Frequency	28	20	24	29	32
Weight	6 (21.4%)	6 (30.0%)	6 (25.0%)	8 (27.6%)	6 (18.8%)
Serum creatinine	3 (10.7%)	2 (10.0%)	4 (16.7%)	5 (17.2%)	3 (9.4%)
Drug data	4 (14.3%)	2 (10.0%)	6 (25.0%)	5 (17.2%)	3 (9.4%)

Table 40 Transplant follow-up data, 480 months

Variable	2017	2018	2019	2020	2021
Frequency	16	15	15	13	20
Weight	3 (18.8%)	4 (26.7%)	3 (20.0%)	3 (23.1%)	7 (35.0%)
Serum creatinine	2 (12.5%)	2 (13.3%)	2 (13.3%)	2 (15.4%)	4 (20.0%)
Drug data	1 (6.3%)	2 (13.3%)	2 (13.3%)	2 (15.4%)	4 (20.0%)

Table 41 Transplant follow-up data, 540 months

Variable	2017	2018	2019	2020	2021
Frequency	0	3	4	4	7
Weight	-	1 (33.3%)	1 (25.0%)	0 (0.0%)	1 (14.3%)
Serum creatinine	-	1 (33.3%)	0 (0.0%)	0 (0.0%)	1 (14.3%)
Drug data	-	1 (33.3%)	1 (25.0%)	0 (0.0%)	1 (14.3%)

Table 42 Transplant follow-up data, 600 months

Variable	2017	2018	2019	2020	2021
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

Table 43 Paediatric assessment at entry

Variable	2017	2018	2019	2020	2021
Frequency	48	45	33	32	33
Height	1 (2.1%)	0 (0.0%)	1 (3.0%)	1 (3.1%)	1 (3.0%)
Weight	1 (2.1%)	0 (0.0%)	1 (3.0%)	0 (0.0%)	1 (3.0%)
Paediatric Assessment at end of each Survey	2 (4.2%)	0 (0.0%)	2 (6.1%)	1 (3.1%)	3 (9.1%)

ANZDATA Missing Data Report

Table 44 Paediatric assessment at entry - mainstream school

Variable	2017	2018	2019	2020	2021
Frequency	3	3	10	18	17
Attendance limited by dialysis? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Attendance limited by renal health? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Supervised education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Additional education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 45 Paediatric assessment at survey

Variable	2017	2018	2019	2020	2021
Frequency	351	360	356	355	358
Height	21 (6.0%)	14 (3.9%)	18 (5.1%)	32 (9.0%)	14 (3.9%)
Weight	21 (6.0%)	14 (3.9%)	14 (3.9%)	31 (8.7%)	12 (3.4%)
Paediatric Assessment at end of each Survey	19 (5.4%)	13 (3.6%)	15 (4.2%)	27 (7.6%)	13 (3.6%)

Table 46 Paediatric assessment at survey - mainstream school

Variable	2017	2018	2019	2020	2021
Frequency	2	4	255	245	259
Attendance limited by dialysis? (If in mainstream school)	0 (0.0%)	0 (0.0%)	2 (0.8%)	4 (1.6%)	5 (1.9%)
Attendance limited by renal health? (If in mainstream school)	0 (0.0%)	0 (0.0%)	2 (0.8%)	4 (1.6%)	5 (1.9%)
Supervised education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	2 (0.8%)	4 (1.6%)	6 (2.3%)
Additional education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	2 (0.8%)	4 (1.6%)	6 (2.3%)

Table 47 Parenthood data

Variable	2017	2018	2019	2020	2021
Frequency	61	52	43	55	55
Pregnancy outcome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	9 (14.8%)	9 (17.3%)	5 (11.6%)	9 (16.4%)	6 (10.9%)
Gestational age (best clinical estimate, weeks)	37 (60.7%)	15 (28.8%)	8 (18.6%)	6 (10.9%)	4 (7.3%)
Diabetes	31 (50.8%)	20 (38.5%)	20 (46.5%)	35 (63.6%)	29 (52.7%)
Hypertension (Somanz 2014 definition)	34 (55.7%)	28 (53.8%)	23 (53.5%)	32 (58.2%)	28 (50.9%)
CYA Immunosuppression at conception	36 (59.0%)	25 (48.1%)	8 (18.6%)	10 (18.2%)	14 (25.5%)
AZA Immunosuppression at conception	34 (55.7%)	22 (42.3%)	7 (16.3%)	9 (16.4%)	13 (23.6%)
Pred Immunosuppression at conception	34 (55.7%)	22 (42.3%)	7 (16.3%)	8 (14.5%)	13 (23.6%)
Tac Immunosuppression at conception	33 (54.1%)	23 (44.2%)	7 (16.3%)	8 (14.5%)	13 (23.6%)
MMF Immunosuppression at conception	35 (57.4%)	26 (50.0%)	8 (18.6%)	9 (16.4%)	14 (25.5%)
Sirol Immunosuppression at conception	36 (59.0%)	27 (51.9%)	9 (20.9%)	10 (18.2%)	14 (25.5%)
Other Immunosuppression at conception	39 (63.9%)	29 (55.8%)	9 (20.9%)	10 (18.2%)	15 (27.3%)
Labour type	39 (63.9%)	27 (51.9%)	24 (55.8%)	31 (56.4%)	31 (56.4%)
Delivery type	39 (63.9%)	27 (51.9%)	23 (53.5%)	32 (58.2%)	31 (56.4%)

Congenital condition present?	35 (57.4%)	18 (34.6%)	5 (11.6%)	6 (10.9%)	6 (10.9%)

Table 48 Parenthood birthweight data

Variable	2017	2018	2019	2020	2021
Frequency	56	48	40	50	50
Weight at birth (gms)	11 (19.6%)	9 (18.8%)	7 (17.5%)	6 (12.0%)	5 (10.0%)

Table 49 Parenthood creatinine prior to conception

Variable	2017	2018	2019	2020	2021
Frequency	19	14	11	18	19
Creatinine prior to conception (umol/L)	3 (15.8%)	1 (7.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 50 Parenthood creatinine post delivery

Variable	2017	2018	2019	2020	2021
Frequency	19	14	11	18	13
Creatinine 3 months post delivery (umol/L)	5 (26.3%)	2 (14.3%)	2 (18.2%)	6 (33.3%)	2 (15.4%)

Table 51 Non-skin cancer data

Variable	2017	2018	2019	2020	2021
Frequency	683	710	689	627	505
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	18 (2.6%)	31 (4.4%)	25 (3.6%)	20 (3.2%)	21 (4.2%)
Cancer staging code	63 (9.2%)	88 (12.4%)	82 (11.9%)	61 (9.7%)	38 (7.5%)
Type 1st treatment	63 (9.2%)	85 (12.0%)	81 (11.8%)	80 (12.8%)	56 (11.1%)